ArticleInternational journal of hematology2013
Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
Article in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- When intestinal ulceration meets hematologic malignancies: clinical features and mortality from a pooled individual-patient data systematic review.Frontiers in immunology · 2026Pooled it
- Effective Management of Refractory Paraneoplastic Vasculitis in Myelodysplastic Syndromes With Azacitidine, Prednisolone, and Azathioprine.Case reports in hematology · 2025Article
- Coombs' test positive autoimmune hemolytic anemia accompanied by myelodysplastic syndrome that became Coombs' test negative after azacitidine administration.Annals of hematology · 2022Article
- Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.Journal of gastroenterology · 2020Article
- Article
- Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.Internal medicine (Tokyo, Japan) · 2019Article
- Myelodysplastic syndrome presenting as a Behçet's-like disease with aortitis.BMJ case reports · 2018Article
- Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.Blood transfusion = Trasfusione del sangue · 2017Article
- Multiple colonic ulcers associated with trisomy 8: serial changes in colonoscopic findings.Clinical journal of gastroenterology · 2016Article
- A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.The American journal of case reports · 2015Article
- Unmet needs in autoimmunity and potential new tools.Clinical reviews in allergy & immunology · 2014Review
- Diagnosis and management of intestinal Behçet's disease.Clinical journal of gastroenterology · 2014Review
- The Simultaneous Elevation of Oxidative Stress Markers and Wilms' Tumor 1 Gene during the Progression of Myelodysplastic Syndrome.Internal medicine (Tokyo, Japan)Article
- Refractory Intestinal Behçet-Like Disease Associated with Trisomy 8 Myelodysplastic Syndrome Resolved by Parenteral Nutrition.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell diseases. It has been reported that several autoimmune diseases are associated with MDS. Recently, the co-occurrence of MDS with trisomy 8 and rare disorders of the immune system, such as Behçet's disease (BD), has been described. Prognosis in the older-onset group of MDS-associated BD is unfavorable. Here, we report a case of MDS-associated intestinal BD treated successfully by azacitidine therapy. A 59-year-old Japanese male suffering from recurrent high fever, melena, and oral and genital ulcerations was diagnosed with MDS with trisomy 8 and intestinal BD by endoscopic and bone marrow examinations. Immunosuppressive therapies, including infliximab, were ineffective. Due to his severe emphysema, the patient was considered ineligible for stem cell transplantation, and azacitidine therapy was initiated. With the exception of fever, the symptoms of intestinal BD improved, and severe malnutrition and anemia were ameliorated. Fluorescence in situ hybridization analyses of the bone marrow before the eighth cycle revealed that the trisomy 8 had not decreased. To our knowledge, this is the first report of azacitidine therapy for MDS-associated BD. We suggest that azacitidine may control intestinal BD by mechanisms other than those responsible for its effect in MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.